Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World melanoma care under the microscope

NCT ID NCT03605771

Knowledge-focused Sponsor: Grupo Español Multidisciplinar de Melanoma Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 17, 2026 · Last updated Sep 18, 2026 · Updated 1 time

Summary

Researchers are studying how advanced and metastatic melanoma is diagnosed and treated in everyday Spanish clinics. The study follows about 400 adults with stage III, metastatic, or unresectable melanoma from their first diagnosis. No experimental treatment is given; instead, the team collects information from medical records to describe who these patients are and what care they receive.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If the study maps real-world melanoma care well, it could help doctors and health systems spot gaps in diagnosis and treatment for advanced disease.
What could go wrong
This study only observes what already happens in clinics, so it cannot prove that any treatment works. Its findings may reflect local Spanish practice and may not apply elsewhere.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2018

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

A 'case' is defined as any patient, diagnosed, treated, or followed in the different health centres where reporting physicians authorised by the GEM group work, who meets the inclusion criteria.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients of legal age with stage III, metastatic, or unresectable melanoma at first diagnosis after January 8, 2018. First diagnosis is understood as: a. Disease onset as metastatic or unresectable disease; b. First metastatic or unresectable relapse in the pre-established dates (after January 8, 2018) in a patient with previous localised melanoma and completely resected on dates before the pre-inclusion period. * Signing the Informed Consent Form (ICF). * A patient may have received the first or subsequent treatments for metastatic or unresectable disease in a hospital other than the centre where the ICF was signed, as long as the patient meets the inclusion criteria 1. * A patient can only sign one ICF (cannot sign an ICF in two different centres). * If a patient signs the ICF in a centre during the first-line therapy and then goes to another centre with consideration for the following lines: If the centre is associated with the GEM-1801 study, researchers will do their best to update the following lines and the patient status, introducing the new information in the centre where the ICF was initially signed. This information will be provided by the patient before contacting the principal investigator and always with prior consent of the patient, who will have previously provided the consent to contact by telephone for this purpose. If this second (or subsequent) centre is not associated with the GEM- 1801 study, this will be considered loss of follow-up, unless the patient returns to the GEM-1801 start centre, wherein the reporting physicians will do their best to update the information from other centres, always with prior patient consent, who will have previously signed the ICF; c) A patient card with the assigned code will be delivered. Exclusion Criteria: * Any patient not complying with inclusion criteria.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer melanoma metastatic melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced cancer Melanoma stage III Melanoma stage IV

Contacts and locations

Locations

  • Clínica Universidad de Navarra

    Pamplona, Spain

  • Complejo Asistencial Universitario de Salamanca

    Salamanca, Castille and León, Spain

  • Complejo Hospitalario de Navarra

    Pamplona, Navarre, Spain

  • Complejo Hospitalario de Pontevedra

    Pontevedra, Pontevedra, 36164, Spain

  • Hospital Clínico San Carlos

    Madrid, 28040, Spain

  • Hospital Clínico Universitario Lozano Blesa

    Zaragoza, Zaragoza, 50009, Spain

  • Hospital Clínico Universitario Virgen de la Arrixaca

    El Palmar, Murcia, 30120, Spain

  • Hospital Clínico Universitario de Valladolid

    Valladolid, Valladolid, 47003, Spain

  • Hospital Costa del Sol

    Marbella, Málaga, Spain

  • Hospital General Universitario Gregorio Marañón

    Madrid, Spain

  • Hospital General Universitario de Valencia

    Valencia, Valencia, Spain

  • Hospital General de Ciudad Real

    Ciudad Real, Castille-La Mancha, Spain

  • Hospital La Ribera

    Alzira, Valencia, 46600, Spain

  • Hospital Lucus Augusti

    Lugo, Lugo, 27003, Spain

  • Hospital San Pedro

    Logroño, La Rioja, 26006, Spain

  • Hospital Universitari Vall d'Hebron

    Barcelona, Barcelona, 08035, Spain

  • Hospital Universitario Araba Txagorritxu Victoria

    Vitoria-Gasteiz, Basque Country, Spain

  • Hospital Universitario La Paz

    Madrid, Madrid, Spain

  • Hospital Universitario La Princesa

    Madrid, Madrid, 28006, Spain

  • Hospital Universitario Marqués de Valdecilla

    Santander, Cantabria, Spain

  • Hospital Universitario Miguel Servet

    Zaragoza, Zaragoza, 500009, Spain

  • Hospital Universitario Puerta de Hierro-Majadahonda

    Majadahonda, Madrid, Spain

  • Hospital Universitario Quirón Dexeus

    Barcelona, Catalonia, Spain

  • Hospital Universitario Ramón y Cajal

    Madrid, Madrid, Spain

  • Hospital Universitario Regional de Málaga

    Málaga, Andalusia, Spain

  • Hospital Universitario Río Hortega

    Valladolid, Castille and León, Spain

  • Hospital Universitario San Pedro Alcántara

    Cáceres, Extremadura, Spain

  • Hospital Universitario Son Llàtzer

    Palma de Mallorca, Palma, 07198, Spain

  • Hospital Universitario Virgen de las Nieves

    Granada, Andalusia, Spain

  • Hospital Universitario de Burgos

    Burgos, Castille and León, Spain

  • Hospital Universitario de Valme

    Seville, Sevilla, Spain

  • Hospital Virgen de la Salud

    Toledo, Toledo, 45004, Spain

  • Hospital Virgen de los Lirios

    Alcoy, Alicante, 03804, Spain

  • Hospital de la Santa Creu y Sant Pau

    Barcelona, Catalonia, Spain

  • Instituto Catalán de Oncología Badalona

    Badalona, Catalonia, Spain

  • Instituto Valenciano de Oncología

    Valencia, Valencia, Spain

  • Onconogranada

    Granada, Andalusia, Spain

  • Onkologikoa

    Donostia / San Sebastian, Guipuzcoa, 20014, Spain

  • Parc Taulí

    Sabadell, Barcelona, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.